Advancing skin cancer treatment through dual drug loading into liposome-derived nanosystems

As a complex disease, skin cancer is a major public health challenge. Recent advances in nano-delivery systems have broadened the possibilities for the development of chemotherapy and immunotherapy. Furthermore, nanovesicles offer a precise, targeted, and effective approach for delivering therapeutic molecules.

The goal of the researchers in this field is to improve the effectiveness of therapy, safeguarding active compounds from degradation, and minimizing side effects. The implementation of the advanced formulations in clinical practice has been slow, mainly due to the difficulty in managing skin cancer therapeutically.

This evaluation investigated how dual-loaded liposomes and similar nanosystems, administered through various routes, can enhance the effectiveness of skin cancer treatment. The characterization of the developed formulations considered factors such as the average particle size, polydispersity index, and zeta potential of the co-loaded nanosystems, along with the encapsulation efficiency of the molecules and the drug release profile. Furthermore, the dual-loaded nanosystems were also evaluated through in vitro and in vivo studies. The use of nanosystems was suggested, featuring characteristics like biocompatibility, the ability to encapsulate both lipophilic and hydrophilic drugs, and enhanced retention and permeability effects. Additionally, liposomal formulations increased the efficacy and safety of drug delivery. The nanosystems enabled simultaneous delivery of drugs, potentially leading to better results by lessening side effects and enhancing synergy.

Therefore, the significant potential of co-delivery nanosystems was shown as a very promising approach to improve skin cancer treatment, emphasizing the synergistic impact.